Lipoproteins and cardiovascular disease risk

Ravi Dhingra, Ramachandran S. Vasan

Producción científica: Chapter


Cardiovascular disease (CVD) risk assessment is complex, with lipoproteins constituting a key part of any prediction algorithm. In addition to circulating lipoprotein fractions, an individual’s CVD risk is also influenced by the concomitant presence or absence of other standard CVD risk factors. In this chapter, we describe the strengths and weaknesses of common circulating lipoproteins that are measured in clinical practice for predicting CVD risk. We also discuss how risk assessment tools utilize lipoprotein values in the general assessment of global CVD risk. We highlight the differences between various guidelines for the management of dyslipidemia specifically related to the measurement of select apolipoproteins for assessing CVD risk, comparing the recommendations from Europe, Canada, and the USA. In the end, we elucidate the concept of “residual risk” that accrues from not reaching the target goals for individual lipoprotein concentrations when all other modifiable risk factors are well controlled.

Idioma originalEnglish (US)
Título de la publicación alojadaDyslipidemias
Subtítulo de la publicación alojadaPathophysiology, Evaluation and Management
EditorialHumana Press
Número de páginas9
ISBN (versión digital)9781607614241
ISBN (versión impresa)9781607614234
EstadoPublished - ene 1 2015
Publicado de forma externa

ASJC Scopus subject areas

  • General Medicine


Profundice en los temas de investigación de 'Lipoproteins and cardiovascular disease risk'. En conjunto forman una huella única.

Citar esto